Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California. Show more
400 Seaport Court, Redwood City, CA, 94063, United States
Market Cap
22.12M
52 Wk Range
$3.10 - $11.86
Previous Close
$3.64
Open
$3.58
Volume
19,866
Day Range
$3.25 - $3.60
Enterprise Value
18.29M
Cash
3.746M
Avg Qtr Burn
-1.147M
Insider Ownership
35.38%
Institutional Own.
2.49%
Qtr Updated
12/31/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
Burixafor Details Multiple myeloma | Phase 2 Update |